Business Context and Reporting Period
Company: Aldeyra Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 25, 2018
Event: Announcement of clinical results from the MESO-2 investigator-sponsored trial of ADX-1612 (ganetespib) for pleural malignant mesothelioma, presented at the International Association for the Study of Lung Cancer Conference.
Key Financial Metrics
This filing is a current report regarding a specific event and does not contain a full set of financial statements. No revenue, profit, cash flow, or margin data is provided in this document.
- Licensing Costs: Upfront license fee paid to Madrigal Pharmaceuticals, Inc. of $250,000.
- Future Obligations: Potential milestone payments to Madrigal of less than $340 million in aggregate (over 80% tied to sales milestones).
- Royalties: High single-digit percentage of net sales for ADX-1612 products; mid-single-digit percentage for other HSP90 Inhibitor products.
- Sublicense Revenue Share: Percentage tiers from mid-twenties to low-single digits based on development stage.
Material Changes
The filing reports the presentation of clinical data for ADX-1612 in combination with pemetrexed and cisplatin or carboplatin. It also discloses the terms of the existing License Agreement with Madrigal Pharmaceuticals, Inc., entered into on December 26, 2016, which grants Aldeyra exclusive worldwide rights to develop and commercialize HSP90 Inhibitors.
Outlook, Risks, and Contingencies
- Development Status: The Company is using commercially reasonable efforts to develop Agreement Products.
- Termination Risks: The Agreement may be terminated by Aldeyra with notice, or by either party for uncured material breach or insolvency. Madrigal retains the right to terminate if Aldeyra challenges the validity of licensed patents.
- Reversion of Rights: In the event of early termination, all licensed and developed rights may revert to Madrigal.
- Confidentiality: Portions of the License Agreement have been redacted pending a Freedom of Information Act confidential treatment request.
Investor Verification Checklist
- Verify the specific clinical outcomes of the MESO-2 trial detailed in the attached press release (Exhibit 99.1).
- Review the full, unredacted License Agreement with Madrigal Pharmaceuticals to understand specific milestone triggers and royalty calculations.
- Assess the Company's current cash position and ability to fund future development given the potential $340 million in milestone obligations.
- Monitor regulatory filings for the status of the confidential treatment request regarding the redacted agreement terms.